News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
565,859 Results
Type
Article (40688)
Company Profile (205)
Press Release (524966)
Section
Business (163361)
Career Advice (2033)
Deals (29819)
Drug Delivery (93)
Drug Development (76190)
Employer Resources (151)
FDA (14658)
Job Trends (12882)
News (289874)
Policy (28463)
Tag
Academia (2285)
Africa (749)
Alliances (42294)
Alzheimer's disease (1024)
Antibody-drug conjugate (ADC) (59)
Approvals (14585)
Arizona (87)
Artificial intelligence (77)
Asia (36705)
Australia (5779)
Bankruptcy (270)
Best Places to Work (9744)
Biosimilars (67)
Biotechnology (114)
C2C Services and Suppliers (52710)
California (1522)
Canada (811)
Cancer (478)
Career advice (1691)
Cell therapy (115)
China (137)
Clinical research (60262)
Collaboration (126)
Colorado (63)
Connecticut (67)
COVID-19 (2349)
Cystic fibrosis (67)
Data (267)
Diabetes (72)
Diagnostics (5007)
Drug pricing (77)
Earnings (60559)
Employer resources (134)
Europe (79492)
Events (80812)
Executive appointments (133)
FDA (14852)
Florida (244)
Funding (131)
Gene therapy (95)
GLP-1 (535)
Government (4002)
Healthcare (15666)
Hotbed/Location (378226)
Illinois (219)
Indiana (119)
Infectious disease (2376)
Inflammatory bowel disease (91)
Interviews (341)
IPO (13306)
Job creations (3249)
Job search strategy (1468)
Kansas (86)
Layoffs (361)
Legal (6093)
Lung cancer (118)
Manufacturing (84)
Maryland (328)
Massachusetts (1233)
Medical device (10025)
Medtech (10030)
Mergers & acquisitions (16399)
Metabolic disorders (261)
Michigan (88)
Minnesota (139)
Neuroscience (1173)
New Jersey (501)
New York (507)
NextGen Class of 2024 (5662)
Non-profit (3769)
North Carolina (515)
Northern California (692)
Obesity (163)
Ohio (91)
Opinion (218)
Patents (69)
Pennsylvania (436)
People (47042)
Pharmaceutical (79)
Phase I (18157)
Phase II (26567)
Phase III (20387)
Pipeline (102)
Policy (61)
Postmarket research (2328)
Preclinical (7261)
Press Release (61)
Rare diseases (129)
Real estate (4989)
Regulatory (19248)
Research institute (2134)
Resumes & cover letters (318)
South America (1030)
Southern California (610)
Startups (3512)
Texas (184)
United States (6898)
Vaccines (459)
Washington State (178)
Weight loss (155)
Date
Today (160)
Last 7 days (600)
Last 30 days (1941)
Last 365 days (32872)
2024 (22772)
2023 (34889)
2022 (45029)
2021 (48522)
2020 (46970)
2019 (40123)
2018 (30670)
2017 (29286)
2016 (28240)
2015 (32618)
2014 (25253)
2013 (20953)
2012 (22320)
2011 (23048)
2010 (20822)
565,859 Results for "ra pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).
June 17, 2024
·
7 min read
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Drug Development
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.
April 8, 2024
·
8 min read
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement.
April 30, 2024
·
5 min read
Pharm Country
Mitsubishi Tanabe Pharma America Celebrates Second Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the two-year launch anniversary of RADICAVA ORS ® (edaravone) in the U.S.
June 17, 2024
·
10 min read
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
Moberg Pharma announces that 17,776,856 warrants of series 2023:1 were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%.
June 24, 2024
·
6 min read
Deals
Rapport Therapeutics and Telix Pharma File IPOs as Number of Biotechs Going Public Slows
Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.
May 20, 2024
·
2 min read
·
Kate Goodwin
1 of 56,586
Next
